AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
INFECTIOUS BURSAL DISEASE VIRUS
4 registrations across 3 African markets— 4 active
Markets with INFECTIOUS BURSAL DISEASE VIRUS
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Nobilis Gumboro 228E Lyophilized for suspension | 🇿🇲Zambia | Intervet South Africa (Pty) Ltd | active | Dec 2030 |
| UNIVAX BD VACCINE | 🇿🇼Zimbabwe | INTERVET S.A (PTY) LTD | active | Dec 2027 |
| CEVAC TRANSMUNE VACCINE | 🇿🇼Zimbabwe | CEVA ANIMAL HEALTH (PTY) LTD | active | Dec 2027 |
| GLOBIVAC IBD MAXIMA Lyophilized Injection | 🇹🇿Tanzania | GLOBION INDIA PRIVATE LIMITED | active | — |
INFECTIOUS BURSAL DISEASE VIRUS in Africa — Regulatory Overview
INFECTIOUS BURSAL DISEASE VIRUS is registered across 3 African markets with 4 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zimbabwe, Tanzania, Zambia. AfricaRegulatory refreshes this data daily from official government sources.
Of the 4 registrations, 4 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.